Abstract
The aim of this study was the evaluation of clinical usage of metalloproteinase (MMP): proMMP-1, MMP-2, MMP-7, MMP-9, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in serum of patients with rectal cancer, as well as the selection of parameters of the greatest diagnostic sensitivity and the determination of their relation with clinicopathological features, what is more, the demonstration whether their concentrations may have a prognostic value in the assessment of disease-free survival (DFS) and overall survival (OS). The study comprised 100 patients with rectal cancer including 29 women and 71 men. The tested group was comprised of qualified patients without distant metastasis (M0). It was demonstrated that in patients with rectal cancer, the concentrations of MMP-9, MMP-7, and proMMP-1 as well as TIMP-1 were significantly higher in comparison to the reference group. On the basis of ROC curves, the greatest diagnostic sensitivity of MMP-9 was demonstrated. When evaluating the correlation of tested parameters with the size of the tumor (T1–T2 vs T3–T4), essential differences were shown for proMMP-1 concentrations. The highest percentage of patients with progression had an increased concentration of MMP-7 and TIMP-1. During a 5-year follow-up, univariate log-rank analysis had shown an essential dependence between the concentration of MMP-7 in men and DSF which was confirmed in Cox multivariate analysis. It was demonstrated that the pretreatment concentration of proMMP-1 may be clinically useful when evaluating the mass of the tumor, whereas MMP-7 may be a prognostic factor for DFS in men with rectal cancer without distant metastasis.
Similar content being viewed by others
References
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;6:1374–403.
Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;12:2893–917.
de Gramont A, de Gramont A, Chibaudel B, et al. GERCOR (French Oncology Research Group). From chemotherapy to targeted therapy in adjuvant treatment for stage III colon cancer. Semin Oncol. 2011;4:521–32.
Dotan E, Cohen SJ. Challenges in the management of stage II colon cancer. Semin Oncol. 2011;4:511–20.
Donada M, Bonin S, Barbazza R, et al. Management of stage II colon cancer—the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol. 2013;13:36.
Duffy MJ, van Dalen A, Haglund C, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (RGTM) guidelines. Eur J Cancer. 2003;39:718–27.
Kaminska J, Nowacki MP, Kowalska M, et al. Clinical significance of serum cytokines measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I—an independent prognostic factor. Tumor Biol. 2005;26:186–94.
Mroczko B, Groblewska M, Okulczyk B, et al. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis. 2010;25(10):1177–84.
Mook OR, Frederiks WM, Van Noorden CJ. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta. 2004;1705:69–89.
Said A, Raufman J, Xie G. The role of matrix metalloproteinases in colorectal cancer. Cancers. 2014;6:366–75.
Lukaszewicz-Zajac M, Mroczko B, Guzinska-Ustymowicz K, et al. Matrix metalloproteinase 2 (MMP-2) and their tissue inhibitor 2 (TIMP-2) in gastric cancer patients. Adv Med Sci. 2013;58:235–43.
Li C-Y, Yuan P, Lin S-S, et al. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumor Biol. 2013;34:735–41.
Polistena A, Cucina A, Dinicola S, et al. MMP7 expression in colorectal tumours of different stages. In vivo. 2014;28:105–10.
Groblewska M, Mroczko B, Gryko M, et al. Serum levels and tissue expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinases 2 (TIMP-2) in colorectal cancer patients. Tumor Biol. 2014;35:3793–80.
Rutkowski A, Zajac L, Pietrzak L, et al. Surgical site infections following short-term radiotherapy and total mesorectal excision: results of a randomized study examining the role of gentamicin collagen implant in rectal cancer surgery. Tech Coloproctol 2014, Jul 4. [Epub ahead of print]
Nesteruk D, Rutkowski A, Fabisiewicz S, et al. Evaluation of prognostic significance of circulating tumor cells detection in rectal cancer patients treated with preoperative radiotherapy: prospectively collected material data. Biomed Res Int. 2014;2014:712827.
Murray D, Morrin M, McDonnell S. Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res. 2004;24:489–94.
Hurst NG, Stocken DD, Wilson S, et al. Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patients. Br J Cancer. 2007;97:971–7.
Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol. 2002;29:78–86.
Jumper C, Cobos E, Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med. 2004;98:173–7.
Oberg A, Hoythya M, Tavelin B, et al. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer. Anticancer Res. 2000;20:1085–91.
Ishida H, Murata N, Hayashi Y, et al. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients. Surg Today. 2003;33:885–92.
Holten-Andersen M, Christensen IJ, Nilbert M, et al. Association between preoperative plasma levels of tissue inhibitor of metalloproteinases 1 and rectal cancer survival. A validation study. Eur J Cancer. 2004;1:64–72.
Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007;121:714–23.
Shiozawa J, Ito M, Nakayama T, et al. Expression of matrix metalloproteinase-1 in human colorectal carcinoma. Mod Pathol. 2000;9:925–33.
Sunami E, Tsuno N, Osada T, et al. MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer. Oncologist. 2000;2:108–11.
Bendardaf R, Buhmeida A, Ristamaki R, et al. MMP-1 (collagenase-1) expression in primary colorectal cancer and its metastases. Scand J Gastroenterol. 2007;42:1473–8.
Langenskiöld M, Ivarsson ML, Holmdahl L, et al. Intestinal mucosal MMP-1—a prognostic factor in colon cancer. Scand J Gastroenterol. 2013;48:563–9.
Miyamoto S, Yano K, Sugimoto S, et al. Matrix metalloproteinase 7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3. Cancer Res. 2004;64:665–71.
Xing XJ, Gu XH, Ma TF. Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis. Tumor Biol 2014; Jul 25[Epub ahead of print]
Luo HZ, Zhou ZG, Yang L, et al. Clinicopathologic and prognostic significance of MMP-7 (matrilysin) expression in human rectal cancer. Jpn J Clin Oncol. 2005;12:739–44.
Pryczynicz A, Gryko M, Niewiarowska K, et al. Immunohistochemical expression of MMP-7 protein and its serum level in colorectal cancer. Folia Histochem Cytobiol. 2013;51:206–12.
Martínez-Fernandez A, García-Albeniz X, Pineda E, et al. Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients. Ann Surg Oncol. 2009;16:1412–20.
Maurel J, Nadal C, Garcia-Albeniz X, et al. Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer. 2007;121(5):1066–71.
Yukawa N, Yoshikawa T, Akaike M, et al. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer. Oncology. 2007;72:205–20.8.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fuksiewicz, M., Kotowicz, B., Rutkowski, A. et al. The matrix metalloproteinase-7 and pro-enzyme of metalloproteinase-1 as a potential marker for patients with rectal cancer without distant metastasis. Tumor Biol. 36, 3629–3635 (2015). https://doi.org/10.1007/s13277-014-3000-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-3000-z